Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 10/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SCN1A | P35498 | 2/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.52 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aluminum Chloride Anhydrous SCHEMBL28726861 | 0.91 | SCN4A (0.46) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL6481244 | 0.81 | ALDH1A1 (0.50) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL3049215 | 0.80 | SCN4A (0.52) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL6470644 | 0.79 | ALDH1A1 (0.53) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL22696387 | 0.79 | SCN4A (0.56) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL11125768 | 0.79 | SMN1; SMN2 (0.42) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL9665266 | 0.78 | SCN5A (0.39) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL2819383 | 0.78 | ALDH1A1 (0.53) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL2094083 | 0.77 | SCN4A (0.54) | SCN4ALMNASCN1ASCN5ASCN9A | |
| SCHEMBL147753 | 0.77 | SCN4A (0.54) | SCN4ALMNASCN1ASCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11603355-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-4118070-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| US-11332446-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3938345-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210309623-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-10-07 | — | — | US | disclosed |
| WO-2021183639-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20210284610-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-2287162-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-4027028-A | HYPOTENSIVE AGENTS | SCIENCE UNION ET CIE (FR) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309623-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPV2 | SCN4A 83/4885LMNA 2067/4885SCN1A 66/4885 |
| US-11603355-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | SCN4A 80/4885LMNA 2685/4885SCN1A 43/4885 |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | SCN4A 180/4885LMNA 4573/4885SCN1A 48/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | SCN4A 80/4885LMNA 2685/4885SCN1A 43/4885 |
| US-20210284610-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPV2 | SCN4A 83/4885LMNA 2067/4885SCN1A 66/4885 |
| US-11332446-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV5, TRPV2 | SCN4A 83/4885LMNA 2067/4885SCN1A 66/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | SCN4A 80/4885LMNA 2685/4885SCN1A 43/4885 |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | SCN4A 2314/4885LMNA 4687/4885SCN1A 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.